Latest news with #IDXX
Yahoo
19-05-2025
- Business
- Yahoo
If You Invested $1000 in Idexx Laboratories a Decade Ago, This is How Much It'd Be Worth Now
For most investors, how much a stock's price changes over time is important. This factor can impact your investment portfolio as well as help you compare investment results across sectors and industries. Another thing that can drive investing is the fear of missing out, or FOMO. This particularly applies to tech giants and popular consumer-facing stocks. What if you'd invested in Idexx Laboratories (IDXX) ten years ago? It may not have been easy to hold on to IDXX for all that time, but if you did, how much would your investment be worth today? With that in mind, let's take a look at Idexx Laboratories' main business drivers. Headquartered in Westbrook, ME, IDEXX Laboratories, Inc. is a developer, manufacturer and distributor of products and services primarily for the companion animal veterinary, livestock and poultry, water testing and dairy markets. The company also sells a series of portable electrolytes and blood gas analyzers for the human point-of-care medical diagnostics operates through four segments:Companion Animal Group (CAG) (91.7% of revenues in 2024, up 1.0% from 2023): This segment provides veterinarians with diagnostic capabilities and information management solutions that enhance the health and well-being of pets. The complementary nature of these products and services provides a unique competitive advantage known as the IDEXX Diagnostic Advantage, providing vets with the tools and services necessary to offer advanced veterinary medical (4.7%, up 2.2%): Through this segment, IDEXX provides innovative testing solutions for easy, rapid and accurate detection and quantification of various microbiological parameters in water, helping ensure water safety for people Poultry and Dairy (LPD) (3.1%, down 6.0%): Within this segment, IDEXX provides diagnostic tests and related instrumentation required to manage the health status of livestock and poultry to improve bovine reproductive efficiency and ensure the quality and safety of milk and food. These products are purchased by the government and private laboratories that provide testing services to cattle, swine and poultry veterinarians, producers and (0.4%, down 20.0%): The company's OPTI Medical operating segment has been combined and presented with the remaining pharmaceutical product line and the out-licensing arrangements in an 'Other' category, primarily because they do not meet the quantitative or qualitative thresholds for reportable segments. While anyone can invest, building a lucrative investment portfolio takes research, patience, and a little bit of risk. If you had invested in Idexx Laboratories ten years ago, you're probably feeling pretty good about your investment today. According to our calculations, a $1000 investment made in May 2015 would be worth $7,661.93, or a 666.19% gain, as of May 19, 2025. Investors should keep in mind that this return excludes dividends but includes price appreciation. The S&P 500 rose 180.69% and the price of gold increased 153.90% over the same time frame in comparison. Analysts are anticipating more upside for IDXX. IDEXX's robust strategic execution is highlighted by new business gains, high customer retention levels and solid net price realization. This underscores the consistent growth in the CAG international business, supported by volume gains and global premium instrument placements. The company's software solutions are facilitating growth by enhancing clinic workflows and promoting greater utilization of diagnostics. Also, the consumable business boosts its top line. Meanwhile, IDEXX's debt-burdened balance sheet raises concern. The company's wide global presence makes it vulnerable to currency fluctuations. Meanwhile, broader macroeconomic issues are slowing its operations. The stock has jumped 25.91% over the past four weeks. Additionally, no earnings estimate has gone lower in the past two months, compared to 7 higher, for fiscal 2025; the consensus estimate has moved up as well. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report IDEXX Laboratories, Inc. (IDXX) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research
Yahoo
15-05-2025
- Business
- Yahoo
5 High-Flying Medical Instrument Stocks to Buy Despite Recent Turmoil
The medical instruments industry is currently undergoing a transformative phase, thanks to the rapid adoption of generative artificial intelligence (genAI) and digital therapeutics, which market watchers expect will take the healthcare industry by storm. Since the beginning of 2023, the industry has been witnessing mass adoption of AI and the Internet of Medical Things in the form of digital healthcare options in hospitals and other healthcare settings. GenAI has begun to showcase its proficiency across a range of healthcare fields, from time-consuming administrative tasks to critical areas such as technological discovery and clinical trials. GenAI, while analyzing vast and complex genetic and molecular data, is expected to help healthcare reach new heights in terms of predictive treatment options and smart hospital systems. At this stage, it should be prudent to invest in stocks from the Zacks-defined Medical Instrument industry with a favorable Zacks Rank. We have selected five such stocks that have provided double-digit returns in the past month during which Wall Street suffered severe volatility. These stocks are: DexCom Inc. DXCM, IDEXX Laboratories Inc. IDXX, NeuroPace Inc. NPCE, Fresenius Medical Care AG FMS and ClearPoint Neuro Inc. CLPT. Each of our picks carries a Zacks Rank #2 (Buy). You can see the complete list of today's Zacks #1 Rank stocks here. The chart below shows the price performance of our five picks in the past month. Image Source: Zacks Investment Research DexCom has benefited from an impressive contribution from the Sensor segment and domestic and international revenue growth have acted as the key catalysts. DXCM's prospects with Stelo as an OTC monitor for type 2 diabetes bode well. DXCM made continued advancements concerning key strategic objectives and ended the quarter with new patient additions. DXCM's slew of tie-ups with AID systems is encouraging. A solid international foothold and robust product portfolio augur well. A strong solvency position is an added plus. DexCom has an expected revenue and earnings growth rate of 14.3% and 23.2%, respectively, for the current year. The Zacks Consensus Estimate for current-year earnings has improved 1.5% over the last 60 days. IDEXX Laboratories' robust strategic execution is highlighted by new business gains, high customer retention levels and solid net price realization. This underscores the consistent growth in the CAG international business, supported by volume gains and global premium instrument placements. IDXX's software solutions are facilitating growth by enhancing clinic workflows and promoting greater utilization of diagnostics. Also, the consumable business boosts IDXX's top line. IDXX is focused on growing its global commercial capability to sustain strong CAG Diagnostics recurring revenue growth. IDEXX Laboratories has an expected revenue and earnings growth rate of 5.8% and 14%, respectively, for the current year. The Zacks Consensus Estimate for current-year earnings has improved 0.4% over the last seven days. NeuroPace operates as a medical device company in the United States. NPCE develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating drug-resistant focal epilepsy. NPCE's RNS System includes RNS neurostimulator, cortical strip and depth leads, and Patient Remote Monitor, as well as other implantable and non-implantable accessories. In addition, NPCE provides physician tablet and patient data management system; and nSight Platform, which facilitates ongoing patient monitoring and streamlines patient support. NPCE sells its products to hospital facilities for initial RNS System implant procedures and for replacement procedures. NeuroPace has an expected revenue and earnings growth rate of 18.1% and 15.1%, respectively, for the current year. The Zacks Consensus Estimate for current-year earnings has improved 12.2% over the last 60 days. Fresenius Medical Care has been benefiting from strong organic growth on the back of improving treatment volumes as well as a stabilizing labor environment in the United States. Continued improvement in these two key factors should be beneficial for FMS in 2025. Overall pricing momentum also supported growth in the Care Enablement segment. FMS' newly implemented operating model led to operational improvements. FMS generated 221 million euros in savings in 2024 by implementing initiatives under the FME25 transformation program. FMS' continued divestment of its noncore and dilutive assets seems promising. Fresenius Medical Care has an expected revenue and earnings growth rate of 1.6% and 28.3%, respectively, for the current year. The Zacks Consensus Estimate for current-year earnings has improved 1.4% over the last seven days. ClearPoint Neuro operates as a medical device company primarily in the United States. CLPT develops and commercializes platforms for performing minimally invasive surgical procedures in the brain under magnetic resonance imaging guided interventions. CLPT offers ClearPoint system, an integrated system for the insertion of deep brain stimulation electrodes, biopsy needles, and laser catheters, as well as the infusion of pharmaceuticals into the brain. ClearPoint Neuro has an expected revenue and earnings growth rate of 24.1% and 11.4%, respectively, for the current year. The Zacks Consensus Estimate for current-year earnings has improved 1.6% over the last 30 days. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Fresenius Medical Care AG & Co. KGaA (FMS) : Free Stock Analysis Report DexCom, Inc. (DXCM) : Free Stock Analysis Report IDEXX Laboratories, Inc. (IDXX) : Free Stock Analysis Report ClearPoint Neuro, Inc. (CLPT) : Free Stock Analysis Report NeuroPace, Inc. (NPCE) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
14-05-2025
- Business
- Yahoo
Is IDEXX Laboratories (IDXX) Outperforming Other Medical Stocks This Year?
For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Idexx Laboratories (IDXX) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question. Idexx Laboratories is one of 1001 individual stocks in the Medical sector. Collectively, these companies sit at #4 in the Zacks Sector Rank. The Zacks Sector Rank includes 16 different groups and is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. The Zacks Rank is a proven system that emphasizes earnings estimates and estimate revisions, highlighting a variety of stocks that are displaying the right characteristics to beat the market over the next one to three months. Idexx Laboratories is currently sporting a Zacks Rank of #2 (Buy). The Zacks Consensus Estimate for IDXX's full-year earnings has moved 1.9% higher within the past quarter. This is a sign of improving analyst sentiment and a positive earnings outlook trend. Our latest available data shows that IDXX has returned about 23.2% since the start of the calendar year. Meanwhile, the Medical sector has returned an average of -6.7% on a year-to-date basis. This means that Idexx Laboratories is outperforming the sector as a whole this year. Another stock in the Medical sector, AngioDynamics (ANGO), has outperformed the sector so far this year. The stock's year-to-date return is 2.6%. In AngioDynamics' case, the consensus EPS estimate for the current year increased 22.5% over the past three months. The stock currently has a Zacks Rank #1 (Strong Buy). Breaking things down more, Idexx Laboratories is a member of the Medical - Instruments industry, which includes 85 individual companies and currently sits at #78 in the Zacks Industry Rank. Stocks in this group have lost about 6.9% so far this year, so IDXX is performing better this group in terms of year-to-date returns. AngioDynamics is also part of the same industry. Investors with an interest in Medical stocks should continue to track Idexx Laboratories and AngioDynamics. These stocks will be looking to continue their solid performance. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report IDEXX Laboratories, Inc. (IDXX) : Free Stock Analysis Report AngioDynamics, Inc. (ANGO) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
04-05-2025
- Business
- Yahoo
Idexx Laboratories price target raised to $460 from $420 at Stifel
Stifel raised the firm's price target on Idexx Laboratories (IDXX) to $460 from $420 and keeps a Hold rating on the shares. The firm says that the company's Q1 results were not surprising, but the stock's reaction was a bit stronger than expected. Stifel will continue to monitor the uptake of Cancer Dx and inVue, but for now the firm believes the near-term contribution is already reflected in estimates. Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter. Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See today's best-performing stocks on TipRanks >> Read More on IDXX: Disclaimer & DisclosureReport an Issue Early notable gainers among liquid option names on May 1st Idexx Laboratories: Stable Performance and Growth Potential Amid Market Challenges Idexx Laboratories reports Q1 EPS $2.96, consensus $2.84 Idexx Laboratories raises 2025 EPS view 19c to $11.93-$12.43, consensus $11.99 Is IDXX a Buy, Before Earnings?
